Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
3(25%)
Results Posted
83%(5 trials)

Phase Distribution

Ph phase_2
2
17%
Ph phase_3
8
67%
Ph phase_4
1
8%
Ph phase_1
1
8%

Phase Distribution

1

Early Stage

2

Mid Stage

9

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
8(66.7%)
Phase 4Post-market surveillance
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

12

all time

Status Distribution
Active(6)
Completed(6)

Detailed Status

Completed6
Not yet recruiting3
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (8.3%)
Phase 22 (16.7%)
Phase 38 (66.7%)
Phase 41 (8.3%)

Trials by Status

recruiting217%
completed650%
active_not_recruiting18%
not_yet_recruiting325%

Recent Activity

Clinical Trials (12)

Showing 12 of 12 trials
NCT07839871Phase 3

Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease

Not Yet Recruiting
NCT06866405Phase 3

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

Recruiting
NCT07543380Phase 3

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

Completed
NCT07653100Phase 3

A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

Recruiting
NCT07819097Phase 3

A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults

Not Yet Recruiting
NCT07693166Phase 4

Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreF

Not Yet Recruiting
NCT05035212Phase 3

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

Active Not Recruiting
NCT05842967Phase 3

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

Completed
NCT04424316Phase 3

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Completed
NCT05886777Phase 2

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Completed
NCT05788237Phase 1

A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults

Completed
NCT04785612Phase 2

Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults

Completed

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12